# US 2013/0243724 A1 · Compositions and methods for inducing migration by dendritic cells and an immune response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0243724 A1
- Document ID: US20130243724A1
- Status: Published application
- Kind: A1
- Application number: 13/825,078
- Filed: 2011-09-19
- Published: 2013-09-19
- Earliest claimed: 2010-09-21
- Assignees: University of Miami
- Inventors: Geoffrey William Stone
- Web page: https://patentgrep.com/patent/US20130243724A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 38/162: {from virus}
- A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
- A61K 38/2006: {IL-1}
- A61K 38/204: {IL-6}
- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/42: Cancer antigens
- C07K 14/005: from viruses
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- C12N 15/85: for animal cells
- A61K 2039/55511: {Organic adjuvants}
- A61K 2239/31: characterized by the route of administration
- C12N 2510/00: Genetically modified cells
- C12N 2710/10043: viral genome or elements thereof as genetic vector
- C12N 2710/10071: Demonstrated in vivo effect
- C12N 2710/16244: Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Compositions and methods of activating dendritic cells with LMP1 and LMP1-activated dendritic cell based compositions and methods are effective for dendritic cell therapy and provide an adjuvant function for vaccine administration. LMP1 or LMP1-CD40 chimeric protein may be used to activate and mature dendritic cells. LMP1 and LMP1-activated dendritic cells act as an adjuvant to enhance the cellular immune response. Also disclosed herein are kits for activating dendritic cells and for preparing a vaccine formulation. Administration of the dendritic cells transfected with LMP1 can induce an immune response against cancer or infection. The mature dendritic cells may comprise an antigen and at least one cytokine in addition to LMP1. Use of LMP1 or LMP1-CD40 provides a way to activate and mature dendritic cells that retain functional and migratory abilities without the side effects that result from maturing the dendritic cells using PGE2

## Claims

### Claim 1

A composition comprising dendritic cells transfected with a nucleic acid encoding LMP1, wherein the dendritic cells are capable of migrating towards lymph node chemokines, secreting IL-12, and activating T cells.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the nucleic acid is RNA.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the nucleic acid encodes a LMP1-CD40 chimeric protein.

### Claim 4 (depends on 1)

The composition of claim 1, further comprising a media formulation comprising at least one cytokine selected from the group consisting of: IL-1β, TNFα, and IL-6.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the at least one cytokine consists of: IL-1β, TNFα, and IL-6.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the dendritic cells are human dendritic cells.

### Claim 7

A method of activating dendritic cells and inducing their migration toward lymph node chemokines, comprising introducing into the dendritic cells a nucleic acid encoding a LMP1-CD40 chimeric protein in the presence of at least one cytokine.

### Claim 8 (depends on 7)

The method of claim 7, wherein the nucleic acid is RNA.

### Claim 9 (depends on 7)

The method of claim 7, wherein the at least one cytokine comprises IL-1β, TNFα, and IL-6.

### Claim 10 (depends on 7)

The method of claim 7, wherein the dendritic cells are human.

### Claim 11 (depends on 1)

A method of inducing an immune response against cancer or infection in a subject, the method comprising administering the composition of claim 1 to the subject in a therapeutically effective amount for inducing an immune response against the cancer or infection in the subject.

### Claim 12 (depends on 11)

The method of claim 11, wherein inducing an immune response against the cancer or the infection in the subject comprises secretion of IL-12 by the dendritic cells and activation of Th1 cells in the subject.

### Claim 13 (depends on 11)

The method of claim 11, wherein the cancer is selected from the group consisting of: melanoma, glioma, prostate cancer, breast cancer, and the infection is selected from the group consisting of: HIV infection and hepatitis C infection.

### Claim 14 (depends on 11)

The method of claim 11, wherein the subject is a human and the dendritic cells are human dendritic cells.

### Claim 15

A vaccine formulation for preventing or treating a disease or condition in a subject, the vaccine comprising a) mature dendritic cells into which a first nucleic acid encoding LMP1 was introduced in the presence of at least one cytokine, the dendritic cells further comprising a second nucleic acid encoding an antigen, wherein the dendritic cells are capable of migrating towards lymph node chemokines, secreting IL-12, and activating T cells; and b) a pharmaceutically acceptable excipient.

### Claim 16 (depends on 15)

The vaccine formulation of claim 15, wherein the first and second nucleic acids are RNA.

### Claim 17 (depends on 15)

The vaccine formulation of claim 15, wherein the subject is a human, the dendritic cells are human dendritic cells, and the first nucleic acid encodes a LMP1-CD40 chimeric protein.

### Claim 18 (depends on 15)

The vaccine formulation of claim 15, wherein the disease or condition is cancer or chronic infection.

### Claim 19

A composition for inducing dendritic cell migration comprising:
A LMP1-CD40 chimeric protein or a nucleic acid encoding a LMP1-CD40 chimeric protein,
IL-1β,
TNFα, and
IL-6,
wherein dendritic cells that are contacted with this composition are capable of migrating towards lymph node chemokines, secreting IL-12, and activating T cells.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the composition is a vaccine adjuvant for preventing or treating a disease or condition in a subject, and further comprises a pharmaceutically acceptable excipient.

### Claim 21

(canceled)

### Claim 22

A kit for activating dendritic cells, the kit comprising: a nucleic acid encoding a LMP1-CD40 fusion protein; at least one cytokine; and a pharmaceutically acceptable excipient.

### Claim 23

(canceled)

### Claim 24 (depends on 22)

The kit of claim 22, wherein the at least one cytokine is selected from the group comprising IL-1β, TNFα, and IL-6.

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)
